Orna Therapeutics Stock

ornatx.comHealthcare / BioTech & PharmaFounded: 2019

Ornatherapeutics, a biotech company headquartered in Cambridge Massachusetts, designs and engineers circular RNA (oRNA) therapeutics that treat various diseases. Ornatherapeutics proprietary disease fighting solutions includes protein expressions used as a delivery method for these solutions. Orna Therapeutics uses three processes, expression of its molecular materials, delivery of these materials, and optimazation of its process through research and development.

Register for Details

For more details on financing and valuation for Orna Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Orna Therapeutics.

Register Today

Orna Therapeutics investors also invested in these private companies


Management Team

Thomas Barnes, PhD
Chief Executive Officer
Amy Becker, PhD
Director, Immunology
Nelson Chau, PhD
Senior Vice President, Platform
Claudia Harper, DVM
Senior Vice President, Preclinical Safety
Nishla Keiser, PhD, JD
Chief Legal Strategy Officer
Robert Mabry, PhD
Chief Scientific Officer
Benjamin Maynor, PhD
Senior Vice President, CMC
John McCabe, CPA
Chief Financial Officer
Liz Molano
Head of People and Culture

Board Members

Daniel Anderson, PhD
Professor, Massachusetts Institute of Technology
Sakae Asanuma, CFA
President, Taiho Ventures
Thomas Ebeling
MPM Capital

Other companies like Orna Therapeutics in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Merck (MRK) Enters Into Circular RNA Collaboration With Orna
Merck (MRK) is set to make an upfront payment of $150 million to Orna for rights to the latter's circular RNA technology to make vaccines and therapeutics for infectious disease and oncology.
Orna Therapeutics Raises $221M in Series B Financing
Orna Therapeutics, a Cambridge, MA-based biotechnology company pioneering a new class of fully engineered circular RNA therapies (oRNA), raised $221m in Series B funding.
Updated on: Sep 24, 2023